Immix Biopharma (IMMX) Analyst & Key Data

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

5

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$12.14

Median Target+44.15%

$17.50

Potential upside vs current price

DCF Value-78.08%

$2.66

Potential downside vs current price

Current Stock Price

$12.14

Median Target+44.15%

$17.50

Potential upside vs current price

DCF Value-78.08%

$2.66

Potential downside vs current price

Analyst Consensus

Buy6 analysts

Buy

Updated Sep 12, 2026

Total Analysts6

Buy

5

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$12.14

Median Target+44.15%

$17.50

Potential upside vs current price

DCF Value-78.08%

$2.66

Potential downside vs current price

Current Stock Price

$12.14

Median Target+44.15%

$17.50

Potential upside vs current price

DCF Value-78.08%

$2.66

Potential downside vs current price

Immix Biopharma, Inc.